JP7826190B2 - 抗ｃｄ４５イムノグロブリンの放射能標識およびその使用方法 - Google Patents

抗ｃｄ４５イムノグロブリンの放射能標識およびその使用方法

Info

Publication number
JP7826190B2
JP7826190B2 JP2022517380A JP2022517380A JP7826190B2 JP 7826190 B2 JP7826190 B2 JP 7826190B2 JP 2022517380 A JP2022517380 A JP 2022517380A JP 2022517380 A JP2022517380 A JP 2022517380A JP 7826190 B2 JP7826190 B2 JP 7826190B2
Authority
JP
Japan
Prior art keywords
μci
seq
amino acid
antibody
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022517380A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022548694A5 (https=
JP2022548694A (ja
Inventor
デール ラディック
サンデシュ セス
Original Assignee
アクティニウム ファーマシューティカルズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アクティニウム ファーマシューティカルズ インコーポレイテッド filed Critical アクティニウム ファーマシューティカルズ インコーポレイテッド
Publication of JP2022548694A publication Critical patent/JP2022548694A/ja
Publication of JP2022548694A5 publication Critical patent/JP2022548694A5/ja
Priority to JP2025160144A priority Critical patent/JP2026047359A/ja
Application granted granted Critical
Publication of JP7826190B2 publication Critical patent/JP7826190B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/289—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD45
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2022517380A 2019-09-17 2020-09-17 抗ｃｄ４５イムノグロブリンの放射能標識およびその使用方法 Active JP7826190B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025160144A JP2026047359A (ja) 2019-09-17 2025-09-26 抗ｃｄ４５イムノグロブリンの放射能標識およびその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962901290P 2019-09-17 2019-09-17
US62/901,290 2019-09-17
PCT/US2020/051324 WO2021055638A1 (en) 2019-09-17 2020-09-17 Radiolabeling of anti-cd45 immunoglobulin and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025160144A Division JP2026047359A (ja) 2019-09-17 2025-09-26 抗ｃｄ４５イムノグロブリンの放射能標識およびその使用方法

Publications (3)

Publication Number Publication Date
JP2022548694A JP2022548694A (ja) 2022-11-21
JP2022548694A5 JP2022548694A5 (https=) 2023-09-27
JP7826190B2 true JP7826190B2 (ja) 2026-03-09

Family

ID=74883490

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022517380A Active JP7826190B2 (ja) 2019-09-17 2020-09-17 抗ｃｄ４５イムノグロブリンの放射能標識およびその使用方法
JP2025160144A Pending JP2026047359A (ja) 2019-09-17 2025-09-26 抗ｃｄ４５イムノグロブリンの放射能標識およびその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025160144A Pending JP2026047359A (ja) 2019-09-17 2025-09-26 抗ｃｄ４５イムノグロブリンの放射能標識およびその使用方法

Country Status (7)

Country Link
US (1) US12605472B2 (https=)
EP (1) EP4031188A4 (https=)
JP (2) JP7826190B2 (https=)
CN (1) CN114728074A (https=)
AU (1) AU2020350677A1 (https=)
CA (1) CA3154732A1 (https=)
WO (1) WO2021055638A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023137335A2 (en) * 2022-01-11 2023-07-20 Actinium Pharmaceuticals, Inc. Methods for treating cd33-positive hematological malignancies
JP2025510189A (ja) 2022-03-24 2025-04-14 アクティニウム ファーマシューティカルズ インコーポレイテッド ヒト化抗ｃｄ４５抗体
WO2025064402A1 (en) * 2023-09-22 2025-03-27 St. Jude Children's Research Hospital, Inc. Method for treating sickle cell disease by targeting senescent cells
CN119842630B (zh) * 2024-12-31 2025-12-26 江苏为真生物医药技术股份有限公司 抗人cd45单克隆抗体杂交瘤细胞株及分泌抗体及其制备方法与应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017155937A1 (en) 2016-03-07 2017-09-14 Actinium Pharmaceuticals, Inc. Stabilized radiolabeled anti-cd45 immunoglobulin compositions
JP2018520207A (ja) 2015-05-21 2018-07-26 アクティニウム ファーマシューティカルズ インコーポレイテッド 結合型モノクローナル抗体の注入投与
WO2019084273A1 (en) 2017-10-25 2019-05-02 Actinium Pharmaceuticals, Inc. METHODS OF ANTI-CD45-BASED LYMPHODEPPLICATION AND USES THEREOF IN COMBINATION WITH ACT-BASED ANTICANCER THERAPIES

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5273738A (en) * 1990-03-03 1993-12-28 Fred Hutchinson Cancer Research Center Radiation delivery to lymphoid and marrow tissues
CN108026526B (zh) * 2015-06-09 2023-05-12 爱迪塔斯医药公司 用于改善移植的crispr/cas相关方法和组合物
AU2016274989A1 (en) 2015-06-12 2017-11-02 Immunomedics, Inc. Disease therapy with chimeric antigen receptor (car) constructs and t cells (car-t) or nk cells (car-nk) expressing car constructs
US20230132400A9 (en) 2017-11-10 2023-04-27 Actinium Pharmaceuticals, Inc. Combination therapy for treatment of a hematological disease
WO2019136422A1 (en) * 2018-01-08 2019-07-11 Actinum Pharmaceuticals, Inc. Combination immunotherapy and chemotherapy for the treatment of a hematological malignancy
CA3137908A1 (en) 2019-04-25 2020-10-29 Actinium Pharmaceuticals, Inc. Compositions and methods of immunodepletion for the treatment of malignant and non-malignant hematological diseases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018520207A (ja) 2015-05-21 2018-07-26 アクティニウム ファーマシューティカルズ インコーポレイテッド 結合型モノクローナル抗体の注入投与
WO2017155937A1 (en) 2016-03-07 2017-09-14 Actinium Pharmaceuticals, Inc. Stabilized radiolabeled anti-cd45 immunoglobulin compositions
WO2019084273A1 (en) 2017-10-25 2019-05-02 Actinium Pharmaceuticals, Inc. METHODS OF ANTI-CD45-BASED LYMPHODEPPLICATION AND USES THEREOF IN COMBINATION WITH ACT-BASED ANTICANCER THERAPIES

Also Published As

Publication number Publication date
US12605472B2 (en) 2026-04-21
WO2021055638A1 (en) 2021-03-25
EP4031188A1 (en) 2022-07-27
AU2020350677A1 (en) 2022-04-14
US20220378955A1 (en) 2022-12-01
CA3154732A1 (en) 2021-03-25
EP4031188A4 (en) 2023-11-01
CN114728074A (zh) 2022-07-08
JP2026047359A (ja) 2026-03-13
JP2022548694A (ja) 2022-11-21

Similar Documents

Publication Publication Date Title
JP7826190B2 (ja) 抗ｃｄ４５イムノグロブリンの放射能標識およびその使用方法
JP2022106807A (ja) Ｃｄ１１７＋細胞を枯渇させるための組成物及び方法
RU2658438C2 (ru) Химерное терапевтическое антитело нн1 против cd-37
EP2705857B1 (en) Radioimmunoconjugates and their use
US20240269314A1 (en) Pyrrolobenzodiazepine-antibody conjugates and uses thereof
KR20190039085A (ko) 세포의 고갈을 위한 조성물 및 방법
TW202011987A (zh) 螯合型放射核種之抗體
Kossman et al. A phase I trial of humanized monoclonal antibody HuM195 (anti-CD33) with low-dose interleukin 2 in acute myelogenous leukemia
US11912780B2 (en) Anti-CD45-based conditioning methods and uses thereof in conjunction with gene-edited cell-based therapies
JP2025126170A (ja) 悪性および非悪性血液疾患の治療のための免疫枯渇の組成物および方法
TW202011988A (zh) 螯合型放射核種之抗體及清除劑
JP2025143266A (ja) 悪性および非悪性血液疾患の治療のための免疫枯渇の組成物および方法
Frankel et al. Cell surface receptor-targeted therapy of acute myeloid leukemia: a review
HK1195736B (en) Radioimmunoconjugates and their use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230919

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230919

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240826

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240828

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250226

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250526

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250926

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260126

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260225

R150 Certificate of patent or registration of utility model

Ref document number: 7826190

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150